Genentech And AbbVie: Venclexta Combo Fails To Extend Survival In Phase III Trial For High-Risk MDS
Neutral
0.0
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with previously untreated higher-risk myelodysplastic syndromes, did not meet its
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
